Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19092603 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | March 2025 | January 2026 | Allow | 10 | 2 | 0 | No | No |
| 19052822 | ADENO-ASSOCIATED VIRUS VARIANT | February 2025 | August 2025 | Allow | 6 | 1 | 1 | No | No |
| 19046064 | SURFACE-MODIFIED VIRAL PARTICLES AND MODULAR VIRAL PARTICLES | February 2025 | September 2025 | Allow | 7 | 2 | 0 | No | No |
| 18965925 | NANOBODY TARGETING INFLUENZA A VIRUS NUCLEOPROTEIN AND APPLICATION THEREOF, AND NUCLEIC ACID ENCODING NANOBODY | December 2024 | August 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18670452 | CONSERVED REGION T CELL VACCINES FOR CORONAVIRUS AND METHODS OF USE | May 2024 | March 2025 | Allow | 10 | 0 | 0 | No | No |
| 18639598 | GROUP B ADENOVIRUS-CONTAINING FORMULATION | April 2024 | March 2026 | Allow | 23 | 2 | 1 | Yes | No |
| 18432991 | COMPOSITIONS AND METHODS FOR REGULATING PRODUCTION OF AN ANTIBODY LIKE PROTEIN AND RIBONUCLEIC ACID | February 2024 | July 2025 | Allow | 18 | 4 | 0 | No | No |
| 18514078 | METHOD FOR INDUCING CELLULAR IMMUNITY TO INFECTION BY SARS-CoV-2 | November 2023 | August 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18305735 | RESTRICTIVE EPITOPE PEPTIDE OF MAJOR HISTOCOMPATIBILITY COMPLEX B2 OF H9N2 SUBTYPE AVIAN INFLUENZA VIRUS AND APPLICATION THEREOF | April 2023 | December 2024 | Abandon | 20 | 3 | 0 | No | No |
| 18186914 | CORONAVIRUS VACCINE | March 2023 | August 2024 | Allow | 17 | 2 | 1 | No | No |
| 18172966 | ADJUVANTED PROTEIN VACCINES COMPRISING MODIFIED FULL-LENGTH SPIKE PROTEIN OF SARS-COV-2 COMPOSITION AND METHODS OF USE | February 2023 | November 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 18165286 | INTERFERON-PRODUCING UNIVERSAL SARBECOVIRUS VACCINES, AND USES THEREOF | February 2023 | August 2024 | Allow | 18 | 2 | 1 | No | No |
| 18000815 | MONO- AND MULTI-VALENT SARS-COV- 2 ADENOVIRAL VECTOR VACCINES AND SARS-COV-2 IMMUNE GLOBULIN AND METHODS OF USE | December 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18071499 | CORONAVIRUS VACCINE | November 2022 | August 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17916788 | COVID-19 VACCINE BASED ON THE MYXOMA VIRUS PLATFORM | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17936273 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONAVIRUSES | September 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17906825 | SARS-CORONAVIRUS 2 (SARS-COV-2) SUBUNIT VACCINE CANDIDATES | September 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17787925 | HEPATITIS A VIRUS PREPARATION METHOD AND HEPATITIS A VIRUS PREPARED ACCORDING TO METHOD | June 2022 | November 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17782121 | VARIANT ONCOLYTIC VACCINIA VIRUS AND METHODS OF USE THEREOF | June 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17778055 | METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES OR VACCINE AND DIAGNOSTIC DEVELOPMENT | May 2022 | December 2025 | Allow | 43 | 1 | 0 | No | No |
| 17745171 | METHOD FOR TREATING INFECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) | May 2022 | December 2024 | Abandon | 31 | 3 | 0 | No | No |
| 17744324 | CELL LINE AND PRODUCING METHOD THEREOF | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17767132 | DUAL VIRUSES AND DUAL ONCOLYTIC VIRUSES AND METHODS OF TREATMENT | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17642717 | RECOMBINANT ONCOLYTIC NEWCASTLE DISEASE VIRUSES WITH INCREASED ACTIVITY | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17633430 | CELL CULTURE MEDIUM FOR USE IN PRODUCING GENE THERAPY PRODUCTS IN BIOREACTORS | February 2022 | September 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17632874 | POTENCY ASSAYS FOR VIRAL VECTOR PRODUCTION | February 2022 | September 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17632907 | ONCOLYTIC VACCINIA VIRUS | February 2022 | November 2025 | Allow | 45 | 2 | 1 | No | No |
| 17630695 | METHOD FOR VIRAL INACTIVATION | January 2022 | November 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17579054 | Multipurpose Compositions for Collecting and Transporting Biological Material | January 2022 | December 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17596839 | LIPID NANOPARTICLE OR LIPOSOME DELIVERY OF HEPATITIS B VIRUS (HBV) VACCINES | December 2021 | December 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17596750 | ARENAVIRUS VECTORS FOR HEPATITIS B VIRUS (HBV) VACCINES AND USES THEREOF | December 2021 | November 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17596589 | SYSTEMS AND METHODS FOR GENERATING BACTERIOPHAGES ADAPTED TO INFECT A TARGET BACTERIAL STRAIN | December 2021 | November 2025 | Allow | 47 | 1 | 0 | No | No |
| 17544416 | COMPOSITIONS AND METHODS TO TREAT VIRAL INFECTION AND CO-MORBIDITIES | December 2021 | December 2024 | Allow | 36 | 3 | 1 | Yes | No |
| 17500778 | NUCLEIC ACID CONSTRUCTS FOR VA RNA TRANSCRIPTION | October 2021 | July 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17448095 | Methods for the Diagnosis and Detection of Viral Analytes | September 2021 | February 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17440452 | MONOCLONAL ANTIBODIES FOR PREVENTION AND TREATMENT OF HERPES SIMPLEX VIRAL INFECTIONS | September 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17432745 | ANTIBODIES | August 2021 | October 2025 | Allow | 50 | 2 | 1 | No | No |
| 17272443 | MONOCLONAL ANTIBODY 2G1 FOR BROAD-SPECTRUM NEUTRALIZATION OF EBOLA VIRUSES AND APPLICATION THEREOF | August 2021 | July 2025 | Allow | 52 | 2 | 0 | No | No |
| 17400136 | METHOD, SYSTEM AND APPARATUS FOR DETECTION | August 2021 | July 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17400086 | METHODS AND KITS FOR DETECTING SARS-CORONAVIRUS-2 ANTIGEN | August 2021 | March 2026 | Abandon | 55 | 2 | 1 | No | No |
| 17429454 | Proliferation Method | August 2021 | February 2025 | Allow | 43 | 1 | 0 | No | No |
| 17427546 | METHODS FOR DETECTION AND CHARACTERIZATION OF ANTI-VIRAL VECTOR ANTIBODIES | July 2021 | February 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17389473 | Lateral Flow Device for Detecting SARS-CoV-2 Antibodies in Human and Animal Samples | July 2021 | August 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17389645 | Quantum Dot Conjugated Virus Spike Protein for Cell-Based Bio-Sensing Systems and Drug Screening | July 2021 | October 2025 | Allow | 51 | 2 | 1 | No | No |
| 17425535 | Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof | July 2021 | November 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17421999 | METHODS FOR SCREENING INHIBITORS AGAINST CHIKUNGUNYA VIRUS AND FOR DETERMINING WHETHER SUBJECTS ARE PREDISPOSED TO INFECTION BY SAID VIRUS | July 2021 | March 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17420444 | COMPOSITIONS AND METHODS FOR URINE SAMPLE STORAGE AND DNA EXTRACTION | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17361486 | VIRUS LIKE NANOPARTICLE COMPOSITIONS AND METHODS THEREOF | June 2021 | July 2024 | Allow | 37 | 1 | 1 | No | No |
| 17418357 | GP38-TARGETING MONOCLONAL ANTIBODIES PROTECT ADULT MICE AGAINST LETHAL CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS INFECTION | June 2021 | October 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17418197 | NOROVIRUS VACCINES | June 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17417455 | RECOMBINANT VIRUSES AND THE USES THEREOF | June 2021 | August 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17414267 | RECOMBINANT AVIAN HERPES VIRUSES CONTAINING MULTIPLE FOREIGN GENES | June 2021 | October 2025 | Abandon | 52 | 2 | 1 | Yes | No |
| 17295798 | ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) | May 2021 | June 2025 | Allow | 49 | 2 | 1 | No | No |
| 17295761 | CELLS FOR THE PRODUCTION OF VIRUSES AND METHODS OF USING THE SAME | May 2021 | June 2025 | Allow | 48 | 2 | 1 | No | No |
| 17295835 | VSV CHIMERIC VECTORS | May 2021 | September 2025 | Allow | 52 | 3 | 1 | No | No |
| 17315055 | METHOD FOR DIAGNOSING SARS-COV-2 INFECTION | May 2021 | March 2025 | Abandon | 46 | 4 | 1 | Yes | No |
| 17245355 | METHODS OF GENERATING VACCINES AGAINST NOVEL CORONAVIRUS, NAMED SARS-COV-2 COMPRISING VARIABLE EPITOPE LIBRARIES (VELs) AS IMMUNOGENS | April 2021 | February 2025 | Abandon | 45 | 3 | 1 | No | No |
| 17246360 | METHODS AND KITS FOR VIRUS DETECTION | April 2021 | January 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17244642 | DYSREGULATION OF TRAUMA REGULATION PATHWAY TREATMENT AND MONITORING TECHNIQUES | April 2021 | July 2024 | Allow | 39 | 3 | 1 | Yes | No |
| 17288227 | ONCOLYTIC VIRUS FOR CANCER THERAPY | April 2021 | January 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17222463 | Bacteriophage-Based Antibodies and Binders | April 2021 | March 2025 | Abandon | 48 | 3 | 1 | Yes | Yes |
| 17200297 | Compositions and Methods for Inducing an Immune Response | March 2021 | December 2024 | Abandon | 45 | 2 | 1 | Yes | No |
| 17271843 | HUMAN MONOCLONAL ANTIBODIES THAT NEUTRALIZE PANDEMIC GII.4 NOROVIRUSES | February 2021 | August 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17180351 | Composition and Methods for Treating Infectious Agents Using Pathogen-specific Antibodies | February 2021 | October 2023 | Abandon | 31 | 4 | 1 | No | No |
| 17055318 | VIRAL VECTORS EXHIBITING IMPROVED GENE DELIVERY PROPERTIES | November 2020 | August 2024 | Allow | 45 | 1 | 1 | No | No |
| 17044645 | NEOADJUVANT CANCER TREATMENT | October 2020 | April 2025 | Abandon | 54 | 3 | 1 | No | No |
| 16980821 | INCREASING TISSUE SPECIFIC GENE DELIVERY BY CAPSID MODIFICATION | September 2020 | April 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 16980282 | ONCOLYTIC VACCINIA VIRUS EXPRESSING IMMUNE CHECKPOINT BLOCKADE FOR CANCER IMMUNOTHERAPY | September 2020 | January 2025 | Abandon | 52 | 1 | 1 | No | No |
| 16978288 | INSECT CELL MANUFACTURED PARTIAL SELF-COMPLEMENTARY AAV GENOMES | September 2020 | July 2025 | Abandon | 58 | 2 | 1 | No | No |
| 16970163 | PROBE FOR UNIVERSAL DETECTION OF CIRCULATING TUMOR CELLS | August 2020 | August 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 16969143 | VIRUS-LIKE NANOCAPSID FOR ORAL DELIVERY OF INSULIN | August 2020 | October 2025 | Abandon | 60 | 2 | 1 | Yes | No |
| 16484487 | REBOOTING OF SYNTHETIC BACTERIOPHAGE GENOME IN L-FORM BACTERIA | August 2019 | January 2025 | Abandon | 60 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SIFFORD, JEFFREY MARK.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SIFFORD, JEFFREY MARK works in Art Unit 1671 and has examined 43 patent applications in our dataset. With an allowance rate of 46.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner SIFFORD, JEFFREY MARK's allowance rate of 46.5% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SIFFORD, JEFFREY MARK receive 1.74 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SIFFORD, JEFFREY MARK is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +26.4% benefit to allowance rate for applications examined by SIFFORD, JEFFREY MARK. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 34.8% of applications are subsequently allowed. This success rate is in the 77% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 57.1% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.